1
|
Kulkarni S, Bhandary D, Singh Y, Monga V, Thareja S. Boron in cancer therapeutics: An overview. Pharmacol Ther 2023; 251:108548. [PMID: 37858628 DOI: 10.1016/j.pharmthera.2023.108548] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 10/05/2023] [Accepted: 10/09/2023] [Indexed: 10/21/2023]
Abstract
Boron has become a crucial weapon in anticancer research due to its significant intervention in cell proliferation. Being an excellent bio-isosteric replacement of carbon, it has modulated the anticancer efficacy of various molecules in the development pipeline. It has elicited promising results through interactions with various therapeutic targets such as HIF-1α, steroid sulfatase, arginase, proteasome, etc. Since boron liberates alpha particles, it has a wide-scale application in Boron Neutron Capture therapy (BNCT), a radiotherapy that demonstrates selectivity towards cancer cells due to high boron uptake capacity. Significant advances in the medicinal chemistry of boronated compounds, such as boronated sugars, natural/unnatural amino acids, boronated DNA binders, etc., have been reported over the past few years as BNCT agents. In addition, boronated nanoparticles have assisted the field of bio-nano medicines by their usage in radiotherapy. This review exclusively focuses on the medicinal chemistry aspects, radiotherapeutic, and chemotherapeutic aspects of boron in cancer therapeutics. Emphasis is also given on the mechanism of action along with advantages over conventional therapies.
Collapse
Affiliation(s)
- Swanand Kulkarni
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, Punjab 151401, India
| | - Dyuti Bhandary
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, Punjab 151401, India
| | - Yogesh Singh
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, Punjab 151401, India
| | - Vikramdeep Monga
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, Punjab 151401, India
| | - Suresh Thareja
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, Punjab 151401, India.
| |
Collapse
|
2
|
Gratal P, Arias-Pérez MS, Gude L. 1H-imidazo[4,5-f][1,10]phenanthroline carbohydrate conjugates: synthesis, DNA interactions and cytotoxic activity. Bioorg Chem 2022; 125:105851. [DOI: 10.1016/j.bioorg.2022.105851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 04/05/2022] [Accepted: 04/29/2022] [Indexed: 11/02/2022]
|
3
|
Ueda H, Suzuki M, Sakurai Y, Tanaka T, Aoki S. Design, Synthesis and Biological Evaluation of Boron‐Containing Macrocyclic Polyamine Dimers and Their Zinc(II) Complexes for Boron Neutron Capture Therapy. Eur J Inorg Chem 2022. [DOI: 10.1002/ejic.202100949] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Hiroki Ueda
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science Kyoto University 2-Asashiro-nishi, Kumatori Osaka 590-0494 Japan
| | - Yoshinori Sakurai
- Institute for Integrated Radiation and Nuclear Science Kyoto University 2-Asashiro-nishi, Kumatori Osaka 590-0494 Japan
| | - Tomohiro Tanaka
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| | - Shin Aoki
- Faculty of Pharmaceutical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
- Research Institute for Science and Technology Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
- Research Institute for Biomedical Sciences Tokyo University of Science 2641 Yamazaki, Noda Chiba 278-8510 Japan
| |
Collapse
|
4
|
Ueda H, Suzuki M, Kuroda R, Tanaka T, Aoki S. Design, Synthesis, and Biological Evaluation of Boron-Containing Macrocyclic Polyamines and Their Zinc(II) Complexes for Boron Neutron Capture Therapy. J Med Chem 2021; 64:8523-8544. [PMID: 34077212 PMCID: PMC8279495 DOI: 10.1021/acs.jmedchem.1c00445] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
Boron neutron capture therapy (BNCT)
is a binary therapeutic method
for cancer treatment based on the use of a combination of a cancer-specific
drug containing boron-10 (10B) and thermal neutron irradiation.
For successful BNCT, 10B-containing molecules need to accumulate
specifically in cancer cells, because destructive effect of the generated
heavy particles is limited basically to boron-containing cells. Herein,
we report on the design and synthesis of boron compounds that are
functionalized with 9-, 12-, and 15-membered macrocyclic polyamines
and their Zn2+ complexes. Their cytotoxicity, intracellular
uptake activity into cancer cells and normal cells, and BNCT effect
are also reported. The experimental data suggest that mono- and/or
diprotonated forms of metal-free [12]aneN4- and [15]aneN5-type ligands are uptaken into cancer cells, and their complexes
with intracellular metals such as Zn2+ would induce cell
death upon thermal neutron irradiation, possibly via interactions
with DNA.
Collapse
Affiliation(s)
- Hiroki Ueda
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-Asashiro-nishi, Kumatori, Osaka 590-0494, Japan
| | - Reiko Kuroda
- Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Tomohiro Tanaka
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Shin Aoki
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.,Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.,Research Institute for Biomedical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| |
Collapse
|
5
|
Itoh T, Tamura K, Ueda H, Tanaka T, Sato K, Kuroda R, Aoki S. Design and synthesis of boron containing monosaccharides by the hydroboration of d-glucal for use in boron neutron capture therapy (BNCT). Bioorg Med Chem 2018; 26:5922-5933. [PMID: 30420329 DOI: 10.1016/j.bmc.2018.10.041] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 10/27/2018] [Accepted: 10/29/2018] [Indexed: 01/18/2023]
Abstract
Boron neutron capture therapy (BNCT) is one of the radiotherapies that involves the use of boron-containing compounds for the treatment of cancer. Boron-10 (10B) containing compounds that can accumulate in tumor tissue are expected to be suitable agents for BNCT. We report herein on the design and synthesis of some new BNCT agents based on a d-glucose scaffold, since glycoconjugation has been recognized as a useful strategy for the specific targeting of tumors. To introduce a boryl group into a d-glucose scaffold, we focused on the hydroboration of d-glucal derivatives, which have a double bond between the C1 and C2 positions. It was hypothesized that a C-B bond could be introduced at the C2 position of d-glucose by the hydroboration of d-glucal derivatives and that the products could be stabilized by conversion to the corresponding boronic acid ester. To test this hypothesis, we prepared some 2-boryl-1,2-dideoxy-d-glucose derivatives as boron carriers and evaluated their cytotoxicity and cellular uptake activity to cancer cells, especially under hypoxic conditions.
Collapse
Affiliation(s)
- Taiki Itoh
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Kei Tamura
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Hiroki Ueda
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Tomohiro Tanaka
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Kyouhei Sato
- Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Reiko Kuroda
- Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan
| | - Shin Aoki
- Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan; Division of Medical-Science-Engineering Cooperation, Research Institute for Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan; Imaging Frontier Center, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan.
| |
Collapse
|
6
|
Satapathy R, Dash BP, Mahanta CS, Swain BR, Jena BB, Hosmane NS. Glycoconjugates of polyhedral boron clusters. J Organomet Chem 2015. [DOI: 10.1016/j.jorganchem.2015.06.027] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
7
|
Overwin H, Wray V, Hofer B. Biotransformation of phloretin by amylosucrase yields three novel dihydrochalcone glucosides. J Biotechnol 2015. [DOI: 10.1016/j.jbiotec.2015.07.002] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
8
|
|
9
|
Boronated carbohydrate derivatives as potential boron neutron capture therapy reagents. Future Med Chem 2013; 5:693-704. [DOI: 10.4155/fmc.13.39] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The treatment of cancer remains one of the most challenging problems for humanity. Boron neutron capture therapy is a binary approach for cancer treatment that is particularly attractive in treating high-grade gliomas and metastatic brain tumors. Among the types of boron-containing molecules used as boron neutron capture therapy agents, boronated carbohydrate derivatives have received significant attention because of their preferential uptake by growing tumor cells. This review provides a summary of the recent developments in the chemistry of carborane-containing carbohydrates.
Collapse
|